15 research outputs found
Population Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling of TicarcillinâClavulanate in Pediatric CF Patients
High dose intermittent ticarcillinâclavulanate administration in pediatric cystic fibrosis patients
AbstractBackgroundThe Intermountain Cystic Fibrosis Pediatric Center utilizes ticarcillinâclavulanate 400mg/kg/day divided every 6h, (maximum 24g/day). This dosing strategy is higher than the Cystic Fibrosis Foundation (CFF) recommendations and the Food and Drug Administration (FDA) approved package labeling. The purpose is to determine the safety of this dosing regimen.MethodsA retrospective study of pediatric cystic fibrosis (CF) patients admitted from January 1, 2005 to December 31, 2009 who received the dosing regimen for at least 7days. Baseline and follow-up laboratory parameters were recorded. Statistical analysis was performed.Results127 patients met inclusion criteria. The mean (±SD) ticarcillin dose was 3.5g (±2.16) every 6h; while the mean (±SD) total ticarcillin dose was 13.5g (±6.5) per day. No significant differences occurred in liver function tests, white blood count, and platelet count from baseline. Serum creatinine showed a statistically significant decrease from baseline.ConclusionsHigher than FDA approved doses of ticarcillinâclavulanate may be safely used in the treatment of exacerbations in pediatric cystic fibrosis patients
Population Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling of TicarcillinâClavulanate in Pediatric CF Patients
Practice-Based Validation of Calcium and Phosphorus Solubility Limits for Pediatric Parenteral Nutrition Solutions
Population Pharmacokinetic and Pharmacodynamic Modeling of High-Dose Intermittent Ticarcillin-Clavulanate Administration in Pediatric Cystic Fibrosis Patients
Background The Intermountain Cystic Fibrosis Pediatric Center utilizes ticarcillin-clavulanate 400 mg/kg/d divided every 6 hours, (maximum 24 g/d). This dosing strategy is higher than the Food and Drug Administration (FDA)âapproved package labeling. We evaluated the microbiologic efficacy of this dosing regimen. Objectives The primary study objective was to predict the pharmacokinetic (PK) and pharmacodynamic (PD) MIC breakpoints (the highest MIC with a probability of target attainment [PTA] of at least 90%) for the bacteriostatic and bactericidal targets of ticarcillin activity against Pseudomonas aeruginosa using the study dosing regimen. A secondary objective was to evaluate the tolerability profile of the higher ticarcillin-clavulanate dosing regimen in children with cystic fibrosis (CF). Methods This was a population-based PK-PD modeling study of pediatric CF patients admitted from January 1, 2005 to December 31, 2009 who received the dosing regimen for at least 7 days. Population PK and PD models were used to estimate PK and PD parameters for 127 clinically evaluable patients. A 10,000-patient Monte Carlo simulation was performed to estimate the target time in which free drug concentrations exceeded the MIC of the infecting organism. The 2 PK-PD targets of microbiologic efficacy included â„30% for bacteriostasis and â„50% for bactericidal effects of ticarcillin-clavulanate at higher than FDA-approved doses. Results A total of 127 patients (age, 0â19 years) met inclusion criteria. Serum concentration levels were modeled in this patient population using published PK parameters with intermittent ticarcillin peak concentrations reaching 288 (93.4) mg/L. The model predicted the PTA of the MICs for P. aeruginosa with a near-maximal bactericidal PK-PD MIC breakpoint of 16 ÎŒg/mL and a bacteriostasis PK-PD MIC breakpoint of 32 ÎŒg/mL. Conclusions The results of our simulation suggest that in this select pediatric population, higher than FDA-approved doses of ticarcillin-clavulanate were effective in achieving bactericidal effects among pseudomonal isolates with MICs \u3c16 ÎŒg/mL. Bacteriostatic and bactericidal effects were not frequently achieved among P. aeruginosa isolates with MICs \u3e32 ÎŒg/mL. Additional studies are warranted to determine the clinical effectiveness of this dosing regimen
Population Pharmacokinetic and Pharmacodynamic Modeling of High-Dose Intermittent Ticarcillin-Clavulanate Administration in Pediatric Cystic Fibrosis Patients
Background The Intermountain Cystic Fibrosis Pediatric Center utilizes ticarcillin-clavulanate 400 mg/kg/d divided every 6 hours, (maximum 24 g/d). This dosing strategy is higher than the Food and Drug Administration (FDA)âapproved package labeling. We evaluated the microbiologic efficacy of this dosing regimen. Objectives The primary study objective was to predict the pharmacokinetic (PK) and pharmacodynamic (PD) MIC breakpoints (the highest MIC with a probability of target attainment [PTA] of at least 90%) for the bacteriostatic and bactericidal targets of ticarcillin activity against Pseudomonas aeruginosa using the study dosing regimen. A secondary objective was to evaluate the tolerability profile of the higher ticarcillin-clavulanate dosing regimen in children with cystic fibrosis (CF). Methods This was a population-based PK-PD modeling study of pediatric CF patients admitted from January 1, 2005 to December 31, 2009 who received the dosing regimen for at least 7 days. Population PK and PD models were used to estimate PK and PD parameters for 127 clinically evaluable patients. A 10,000-patient Monte Carlo simulation was performed to estimate the target time in which free drug concentrations exceeded the MIC of the infecting organism. The 2 PK-PD targets of microbiologic efficacy included â„30% for bacteriostasis and â„50% for bactericidal effects of ticarcillin-clavulanate at higher than FDA-approved doses. Results A total of 127 patients (age, 0â19 years) met inclusion criteria. Serum concentration levels were modeled in this patient population using published PK parameters with intermittent ticarcillin peak concentrations reaching 288 (93.4) mg/L. The model predicted the PTA of the MICs for P. aeruginosa with a near-maximal bactericidal PK-PD MIC breakpoint of 16 ÎŒg/mL and a bacteriostasis PK-PD MIC breakpoint of 32 ÎŒg/mL. Conclusions The results of our simulation suggest that in this select pediatric population, higher than FDA-approved doses of ticarcillin-clavulanate were effective in achieving bactericidal effects among pseudomonal isolates with MICs \u3c16 ÎŒg/mL. Bacteriostatic and bactericidal effects were not frequently achieved among P. aeruginosa isolates with MICs \u3e32 ÎŒg/mL. Additional studies are warranted to determine the clinical effectiveness of this dosing regimen